135 related articles for article (PubMed ID: 24824005)
21. ASO Author Reflections: Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma-Predictors of Disease Progression and Performance Status Decline.
Paniccia A; Zureikat A
Ann Surg Oncol; 2020 Aug; 27(8):2972-2973. PubMed ID: 32124127
[No Abstract] [Full Text] [Related]
22. Pancreatic ductal adenocarcinoma: metastatic disease.
Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
[TBL] [Abstract][Full Text] [Related]
23. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
[TBL] [Abstract][Full Text] [Related]
24. [Pancreatic Cancer with Liver Metastasis Treated with Radical Surgery after Chemotherapy].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Inatome J; Naito A; Murakami K; Kagawa Y; Takeno A; Egawa C; Kato T; Tamura S
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1975-1977. PubMed ID: 28133194
[TBL] [Abstract][Full Text] [Related]
25. Reply to letter: "Retrospective studies and pancreatic adenocarcinoma: how far can we backdate?".
Konstantinidis IT; Ferrone CR
Ann Surg; 2015 Mar; 261(3):e84. PubMed ID: 24368656
[No Abstract] [Full Text] [Related]
26. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma.
Wright MJ; Overton HN; Teinor JA; Ding D; Burkhart RA; Cameron JL; He J; Wolfgang CL; Weiss MJ; Javed AA
J Gastrointest Surg; 2020 Jul; 24(7):1590-1596. PubMed ID: 31270718
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic ductal adenocarcinoma: is a cure possible?
Ansari D; Andersson R
Future Oncol; 2017 Apr; 13(10):863-865. PubMed ID: 28266248
[No Abstract] [Full Text] [Related]
28. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
29. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice.
Schizas D; Koumpoura A; Galari M; Economopoulou P; Vailas M; Sotiropoulou M; Dimitroulis D; Maroulis I; Felekouras E
Per Med; 2021 Sep; 18(6):613-627. PubMed ID: 34676789
[TBL] [Abstract][Full Text] [Related]
30. ASO Author Reflections: Prognostic Index after Neoadjuvant Chemotherapy (PINC) in Pancreatic Ductal Adenocarcinoma as Novel Tumor Regression Grading System.
Redegalli M; Schiavo Lena M
Ann Surg Oncol; 2022 Jun; 29(6):3503. PubMed ID: 35187623
[No Abstract] [Full Text] [Related]
31. Long-term survival (superior to 20 years) after pancreaticoduodenectomy for pancreatic duct adenocarcinoma: report of two cases.
Naseef O; Adham M; Hervieu V; Le Borgne J; Partensky C
Hepatogastroenterology; 2008; 55(84):1110-1. PubMed ID: 18705340
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
33. Intraductal and cystic tubulopapillary adenocarcinoma of the pancreas--a possible variant of intraductal tubular carcinoma.
Königsrainer I; Glatzle J; Klöppel G; Königsrainer A; Wehrmann M
Pancreas; 2008 Jan; 36(1):92-5. PubMed ID: 18192889
[No Abstract] [Full Text] [Related]
34. Retrospective studies and pancreatic adenocarcinoma: how far can we backdate?
Ausania F
Ann Surg; 2015 Mar; 261(3):e84. PubMed ID: 24608511
[No Abstract] [Full Text] [Related]
35. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
Sclafani F; Iyer R; Cunningham D; Starling N
Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
[TBL] [Abstract][Full Text] [Related]
37. Borderline resectable pancreatic cancer.
Hackert T; Ulrich A; Büchler MW
Cancer Lett; 2016 Jun; 375(2):231-237. PubMed ID: 26970276
[TBL] [Abstract][Full Text] [Related]
38. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer.
Kosuge T; Kiuchi T; Mukai K; Kakizoe T;
Jpn J Clin Oncol; 2006 Mar; 36(3):159-65. PubMed ID: 16490736
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Okada K; Takahashi S; Sueda T
J Surg Oncol; 2018 Dec; 118(7):1105-1114. PubMed ID: 29878355
[TBL] [Abstract][Full Text] [Related]
40. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
